8-KOther Events

Guardant Health, Inc. 8-K Report, Corporate Update (Apr 1, 2019)

Filed April 1, 2019For Securities:GH

Summary

Guardant Health, Inc. announced a significant development on March 28, 2019, regarding a draft Local Coverage Determination (LCD) from Palmetto GBA, a Medicare Administrative Contractor. This draft LCD proposes to expand Medicare coverage for Guardant360®, the Company's liquid biopsy assay, beyond advanced non-small cell lung cancer (NSCLC) to cover over a dozen other advanced solid tumor cancer types. This expansion is specifically targeted at Medicare beneficiaries with advanced cancers who require next-generation sequencing but have insufficient or unavailable tissue samples, and are candidates for guideline-recommended treatments. If finalized, this expanded coverage would represent a substantial growth opportunity for Guardant Health, potentially increasing the addressable market for its Guardant360® assay. The draft LCD addresses a critical unmet need for patients where obtaining adequate tumor tissue is challenging, such as in cases of advanced or metastatic disease. Investors should note that this is a draft determination and subject to public comment and potential finalization, meaning there is no guarantee it will be implemented as proposed.

Key Highlights

  • 1Palmetto GBA, a Medicare Administrative Contractor, has issued a draft Local Coverage Determination (LCD) proposing expanded Medicare coverage for Guardant360®.
  • 2The draft LCD would broaden coverage for Guardant360® from advanced NSCLC to over a dozen advanced solid tumor cancer types.
  • 3The proposed coverage targets Medicare patients with insufficient or unavailable tumor tissue samples who are candidates for guideline-recommended treatments.
  • 4This expansion addresses a significant patient population where tissue biopsies are challenging or impossible.
  • 5The draft LCD, if finalized, represents a substantial potential increase in Guardant360®'s addressable market.
  • 6The finalization of the LCD is subject to public comment and Palmetto GBA's ultimate decision, with no assurance of implementation.
  • 7The filing includes standard forward-looking statements regarding the potential coverage expansion and associated risks.

Frequently Asked Questions

The draft LCD, if finalized, would significantly expand Medicare coverage for Guardant360®, the Company's liquid biopsy assay, to include over a dozen advanced solid tumor cancer types beyond its current coverage for advanced NSCLC. This is a crucial development as it addresses a large patient population for whom traditional tissue biopsies are difficult or impossible to obtain, and it could substantially increase the addressable market for Guardant360®.

The draft LCD would apply to advanced cancer patients covered by Medicare who require next-generation sequencing of their tumor tissue but have insufficient or unavailable tissue samples. These patients must also be candidates for FDA-approved treatments that are recommended by the National Comprehensive Cancer Network guidelines as category 1 or 2A.

No, the expansion of Medicare coverage is not guaranteed. The document explicitly states that the draft LCD is subject to public comment and Palmetto GBA's finalization process. There can be no assurances that Palmetto GBA will finalize and implement the draft LCD as proposed. Investors should monitor the finalization status of this determination.

If the LCD is finalized, Guardant Health could see a significant increase in the utilization and reimbursement of its Guardant360® assay, particularly among Medicare beneficiaries with a wider range of advanced solid tumors. This would validate the clinical utility and economic value of their liquid biopsy technology for a broader patient population and potentially drive substantial revenue growth.